B1Q
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more
B1Q (B1Q) - Total Liabilities
Latest total liabilities as of September 2025: €40.75 Million EUR
Based on the latest financial reports, B1Q (B1Q) has total liabilities worth €40.75 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
B1Q - Total Liabilities Trend (2021–2024)
This chart illustrates how B1Q's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
B1Q Competitors by Total Liabilities
The table below lists competitors of B1Q ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ImpediMed Limited
PINK:IPDQF
|
USA | $21.16 Million |
|
Daily Polymer
TWO:4716
|
Taiwan | NT$636.29 Million |
|
Ramssol Group Bhd
KLSE:0236
|
Malaysia | RM17.59 Million |
|
Ten Ren Tea Co Ltd
TW:1233
|
Taiwan | NT$854.33 Million |
|
TGS Dis Ticaret AS
IS:TGSAS
|
Turkey | TL17.82 Billion |
|
Dmg Blockchain Solutions Inc
OTCQB:DMGGF
|
USA | $17.44 Million |
|
Delta Lithium Ltd
AU:DLI
|
Australia | AU$6.36 Million |
|
Aallon Group Oyj
HE:AALLON
|
Finland | €19.44 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down B1Q's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how B1Q's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for B1Q (2021–2024)
The table below shows the annual total liabilities of B1Q from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €26.87 Million | +41.09% |
| 2023-12-31 | €19.05 Million | +3.48% |
| 2022-12-31 | €18.41 Million | +54.38% |
| 2021-12-31 | €11.92 Million | -- |